% | $
Quotes you view appear here for quick access.

BioMimetic Therapeutics Inc. Message Board

sophia.leghorn 3 posts  |  Last Activity: Jul 11, 2016 10:23 AM Member since: Feb 22, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • sophia.leghorn by sophia.leghorn Jun 29, 2016 4:04 PM Flag

    it's over. It's a stampede for the exits while energy prices have rebounded -- wow. The energy loans are priced to zero. If management sold the energy assets for 25 cents on the dollar, the stock would go up. One has to wonder why management didn't sell them as soon as they were charged with doing so. Instead shareholders were given this cinderella story about how Castex was the portfolio's best investment. What a laugh. Castex must be swamped with debt, something management would have known about.

  • Reply to

    The action is telling me...

    by sophia.leghorn Jun 29, 2016 4:04 PM
    sophia.leghorn sophia.leghorn Jun 30, 2016 9:20 AM Flag

    100% write-off = $1.93
    75% = $2.65
    50% = $3.37
    41% = $3.62
    25% = $4.08
    These are write-offs from the latest 10Q fair values which have already been marked down substantially. A sale at 41% markdown from current fair value is a give away. An orderly liquidation could double the stock price, and it could happen because lenders want out. If OHAI can't borrow, it can't make a decent return to justify continuing. They'd wind down.

    Sentiment: Strong Buy

  • sophia.leghorn by sophia.leghorn Jul 11, 2016 10:23 AM Flag

    I've written about this before. Cobiprostone development is a waste of time and money. Better to preserve cash and focus on growing Lubipropstone, to repurchase shares, and then to be bought out. Management so far has a poor record. They have shown they can continue to monetize Lubiprostone, but they haven't lived up to the initial hype about growing into the gastro space or into any other space.

    Sentiment: Buy